Main Clinical, Histopathologic, and Biochemical Features of Patients (n = 18)
| Feature | Data |
| Age (mo) | 34 ± 19 (12–72) |
| Sex, male | 12 (67) |
| Histopathology | |
| Undifferentiated | 6 (33) |
| Poorly differentiated | 9 (50) |
| Unknown | 3 (17) |
| Stage | |
| 3 | 4 (22) |
| 4 | 14 (78) |
| Treatment | |
| NB AR 01 | 15 (83) |
| LINES/personalized | 2/1 (17) |
| MYC amplification | 10 (56) |
| Lactate dehydrogenase (UI/L), median (IQR) | median, 2,890 (IQR, 1,506–5,275) |
| Homovanillic acid levels (μmol/mmol creatinine), median (IQR) | median, 66.7 (IQR, 32.0–76.6) |
| Vanilmandelic acid levels (μmol/mmol creatinine), median (IQR) | median 26.1 (IQR, 5.3–123.9) |
| 18F-DOPA WBMB score | |
| Before induction chemotherapy | 191.9 ± 349.1 (0–1,120) |
| After induction chemotherapy | 18.2 ± 43.1 (0–169) |
| 123I-MIBG WBS score | |
| Before induction chemotherapy | 24.7 ± 20.9 (0–58) |
| After induction chemotherapy | 3.6 ± 9.9 (0–42) |
Continuous data are mean ± SD followed by range in parentheses; count data are number followed by percentage in parentheses (unless otherwise noted).
LINES = Low and Intermediate Risk Neuroblastoma European Study; IQR = interquartile range.